ANTICOAGULANTS IN ACUTE CORONARY SYNDROME

Abstract

Clinical efficacy of unfractionated and low molecular heparins in acute coronary syndrome is discussed. New synthetic heparin derivative fondaparinux (Arixtra) is focused. Author’s brief experience of fondaparinux clinical implementation is presented.

Keywords

• acute coronary syndrome
• anticoagulants
• fondaparinux